Anticoagulant counter ion impact on bioanalytical LC–MS/MS assay performance: additional validation required?

BioanalysisVol. 3, No. 21 EditorialAnticoagulant counter ion impact on bioanalytical LC–MS/MS assay performance: additional validation required?Carl Johan Sennbro, Magnus Knutsson, Philip Timmerman & Peter van AmsterdamCarl Johan Sennbro† Author for correspondenceActive Biotech AB, Scheelevägen 22, S-22007 Lund, Sweden. Search for more papers by this authorEmail the corresponding author at carl-johan.sennbro@activebiotech.com, Magnus KnutssonFerring Pharmaceuticals A/S, Kay Fiskers Plads 11, DK- 2300 Copenhagen S, DenmarkSearch for more papers by this author, Philip TimmermanJanssen Research & Development, Turnhoutseweg 30, B-2340 Beerse, BelgiumSearch for more papers by this author & Peter van AmsterdamAbbott Healthcare Products BV, CJ van Houtenlaan 36, Weesp 1381CP, The NetherlandsSearch for more papers by this authorPublished Online:10 Nov 2011https://doi.org/10.4155/bio.11.240AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleBibliography1 US FDA. Center for Drug Evaluation and Research. Center for Veterinary Medicine. Guidance for Industry – Bioanalytical Method Validation (2001).Google Scholar2 European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on Bioanalytical Method Validation (2011).Google Scholar3 Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays. Pharm. Res.24,1962–1973 (2007).Crossref, Medline, CAS, Google Scholar4 Savoie N, Booth BP, Bradley T et al. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis1(1),19–30 (2009).Link, CAS, Google Scholar5 Sennbro CJ, van Amsterdam P, Timmerman P et al. Comparison of anticoagulant counterion impact on bioanalytical LC–MS/MS assays; results from surveys within European Bioanalysis Forum. Bioanalysis3(21),2393–2399 (2011).Link, CAS, Google Scholar6 Bergeron M, Bergeron A, Furtado M et al. Impact of plasma and whole-blood anticoagulant counterion choice on drug stability and matrix effects during bioanalysis. Bioanalysis1,537–548 (2009).Link, CAS, Google Scholar7 Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L et al. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. Clin. Ther.31(9),2002–2011 (2009).Crossref, Medline, CAS, Google Scholar8 Abbott R, Gordon B, van Amsterdam P et al. Conference report: from challenges to solutions. Bioanalysis3,833–838 (2011).Link, CAS, Google Scholar9 Sennbro CJ (on behalf of European Bioanalysis Forum). Choice of anticoagulant and comparison of counterions – results from two European Bioanalysis Forum surveys. Presented at: The EBF Open Symposium. Barcelona, Spain, 2 December 2010.Google ScholarFiguresReferencesRelatedDetailsCited ByValidation of bioanalytical chromatographic methods for the quantification of drugs in biological fluidsBioanalytical Method Development and Validation for the Determination of Vasopressin Receptor Antagonist Conivaptan in Mouse Plasma at NanoLevel and its Pharmacokinetic ApplicationCurrent Analytical Chemistry, Vol. 15, No. 5Development and validation of an HPLC–MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study2 May 2018 | Chemistry Central Journal, Vol. 12, No. 1Proposal for risk-based scientific approach on full and partial validation for general changes in bioanalytical methodAyumi Mochizuki, Katsunori Ieki, Hiroshi Kamimori, Akemi Nagao, Keiko Nakai, Akira Nakayama & Eitaro Nanba10 April 2018 | Bioanalysis, Vol. 10, No. 8Development and validation of HPLC-MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study16 June 2017 | Biomedical Chromatography, Vol. 31, No. 11Selective Analysis of Dopamine Receptor Antagonist LE300 and its N-Methyl Metabolite in Mouse Sera at the Trace Level by HPLC–Fluorescence Detection21 March 2015 | Chromatographia, Vol. 78, No. 9-10Selective microemulsion liquid chromatography analysis of dopamine receptor antagonist LE300 and its N-methyl metabolite in mouse sera by using a monolithic silica columnJournal of Chromatography B, Vol. 989Message from the editorsKasumi Crews & Bethany Small5 January 2015 | Bioanalysis, Vol. 7, No. 1Bottlenecks in bioanalysis: where do they come from and how to remove them?24 October 2014Small Molecule Specific Run Acceptance, Specific Assay Operation, and Chromatographic Run Quality Assessment: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Teams25 June 2014 | The AAPS Journal, Vol. 16, No. 5Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effectJournal of Chromatography A, Vol. 1353Stability: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team19 February 2014 | The AAPS Journal, Vol. 16, No. 3Evaluation and Elimination of Matrix Effects in LC-MS Bioanalysis30 August 2013Current Understanding of Bioanalytical Assay Reproducibility: Incurred Sample Reanalysis, Incurred Sample Stability, and Incurred Sample Accuracy30 August 2013The European Bioanalysis Forum community’s evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method ValidationPeter van Amsterdam, Arjen Companjen, Margarete Brudny-Kloeppel, Michaela Golob, Silke Luedtke & Philip Timmerman13 March 2013 | Bioanalysis, Vol. 5, No. 6Managing scientific, technical and regulatory innovation in regulated bioanalysis: a discussion paper from the European Bioanalysis ForumPhilip Timmerman, Neil Henderson, John Smeraglia, Hans Mulder, Benno Ingelse, Margarete Brudny-Kloeppel & Arjen Companjen21 January 2013 | Bioanalysis, Vol. 5, No. 2Confirmation of no impact from different anticoagulant counter ions on bioanalytical methodAnnik Bergeron, Mélanie Bergeron & Fabio Garofolo26 April 2012 | Bioanalysis, Vol. 4, No. 8Anticoagulant counter ion impact on bioanalytical LC–MS/MS assays: results from discussions and experiments within the European Bioanalysis ForumCarl Johan Sennbro, Magnus Knutsson, Peter van Amsterdam & Philip Timmerman10 November 2011 | Bioanalysis, Vol. 3, No. 21 Vol. 3, No. 21 Follow us on social media for the latest updates Metrics Downloaded 1,139 times History Published online 10 November 2011 Published in print November 2011 Information© Future Science LtdFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download